These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27261682)

  • 1. Progressive Multiple Sclerosis.
    Willis MA; Fox RJ
    Continuum (Minneap Minn); 2016 Jun; 22(3):785-98. PubMed ID: 27261682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive Multiple Sclerosis.
    Ontaneda D
    Continuum (Minneap Minn); 2019 Jun; 25(3):736-752. PubMed ID: 31162314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Relapsing Multiple Sclerosis.
    Jones DE
    Continuum (Minneap Minn); 2016 Jun; 22(3):744-60. PubMed ID: 27261680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of relapses of multiple sclerosis (a review)].
    Brkovich RR; Totolian NA; Sokolov AIu; Ignatov IuD; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):69-77. PubMed ID: 24416811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
    Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
    Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current questions of multiple sclerosis: the secunder progressive form of the disease].
    Vécsei L
    Ideggyogy Sz; 2020 Jan; 73(1-2):7-14. PubMed ID: 32057199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Multiple Sclerosis Relapses.
    Repovic P
    Continuum (Minneap Minn); 2019 Jun; 25(3):655-669. PubMed ID: 31162310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Multiple Sclerosis Relapse.
    Berkovich RR
    Continuum (Minneap Minn); 2016 Jun; 22(3):799-814. PubMed ID: 27261683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
    Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
    Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differential influence of immune therapy on relapses and progression in multiple sclerosis: interpretation and therapeutic consequences].
    Kornhuber ME; Presek P; Zierz S
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):143-9. PubMed ID: 15747223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.